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Abstract: Exposure of a drug to U V  irradiation could affect its physicochem ical properties. H ence, 
photostability testing is essential for topically adm inistered drugs. Tazarotene, a receptor-selective, 
th ird-generation retinoid, is com m only used to treat acne vulgaris and psoriasis. In the present 
study, an in-depth analysis of the photostability  of tazarotene in ethanolic solution in  the presence 
of zinc oxide and/or titanium  dioxide as w ell as benzophenone-type U V  filters w as perform ed. 
E leven presum ed products w ere derived from  the photocatalytic degradation of tazarotene using 
ultra-perform ance liquid chrom atography-tandem  mass spectrometry, and transform ation pathways 
were proposed. The degradation process m ainly affected the 4,4-dim ethyl-3,4-dihydro-2H -thiopyran 
moiety. The fragm ents m ost susceptible to oxidation w ere the m ethyl groups and the sulfur 
atom . M oreover, in the presence of su lisobenzone, under U V  irradiation, tazarotene w as 
subjected to a degradation process, w hich  resulted in tw o photodecom position products. In  silico  
studies perform ed by  O SIR IS Property Explorer dem onstrated that five of the degradation 
products could be harm ful in  term s of the reproductive effects, w hich  are associated w ith  
3,4-dihydro-6-m ethyl-2H -1-benzothiopyran 1,1-dioxide, w hile one of them  dem onstrated potential 
irritant activity. The cytotoxic properties of the degradation products of tazarotene were assessed by 
M TT assay on a panel of hum an adherent cancer cells. Tim e- and concentration-dependent grow th 
inhibition w as evidenced in ovary (A2780) and breast (MDA-M B-231) cancer cell lines. The potential 
im plication of the outcom es of the present research requires further studies m ainly  concerning the 
photostability of tazarotene in the topical form ulations.
Keyw ords: tazarotene; photostability studies; photocatalytic degradation; benzophenones; TiO2; ZnO
1. Introduction
Tazarotene (ethyl 6-[2-(4,4-dim ethyl-2,3-dihydrothiochrom en-6-yl)ethynyl]pyridine-3-carboxylate)
is a th ird-generation topical retinoid, w hich is applied to the skin. It is a prodrug, w hich  undergoes
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in vivo deesterification in  its active form — the cognate carboxylic acid of tazarotene [1]. Tazarotene 
acid selectively binds to the retinoic acid  receptors— R A R -ß and R A R -y [2,3 ]. This drug is used in 
the treatm ent of m ild-to-m oderate facial acne vulgaris and plaque psoriasis affecting nearly  20% of 
the body surface [4- 6]. Acne vulgaris is a com m on, chronic skin disease, w hich affects approxim ately 
90%  of hum ans across the w orld  at som e p oint in their lives. Topical retinoids are currently  used in 
the first-line treatm ent of the disease. Furtherm ore, tazarotene is used to treat other skin conditions 
such as photoaging and facial m ottled hyper- and hypopigm entation [7]. It slightly penetrates across 
the skin, and 10 h  after its application, ~ 2 % of the dose reaches the viable epiderm is and derm is [8 ]. 
Tazarotene gel is also used w ith narrow-band UVB phototherapy for psoriasis because it enhances the 
efficiency of the therapy and enables a significant reduction of the irradiation dose [9,10] . Like other 
topical retinoids, tazarotene could cause photosensitivity  reactions— generally  m ild and reversible 
phototoxic or photoallergic reactions— and display m inor photoirritant potential [1, 11,12].
Besides, topical photoprotection is an extrem ely im portant area of derm atologic research on 
skin cancer prevention strategies [13]. A  better understanding of the potential interactions betw een 
different substances applied sim ultaneously to the skin, e.g. UV absorbers and active pharm aceutical 
ingredients, is essential for ensuring the safe and effective adm inistration of drug products [14]. 
The behavior of these substances is not predictable from  independent photostability  testing [15,16]. 
H ence, it is im perative to evaluate the com binations of substances used in the form ulations as w ell as 
active pharm aceutical ingredients used w ith cosm etic ingredients [17,18]. The previous investigation 
of the photostability of terbinafine, in both solutions and formulations in the presence of UV absorbers 
such as TiO2, ZnO , avobenzone, 3-(4-m ethylbenzylidene)cam phor, octocrylene, benzophenone-1, 
and benzophenone-2, show ed that U V  absorbers had a d iverse im pact on terbinafine stability [19]. 
It should be em phasized that photostability testing is an integral part of the stability studies included 
in the Q 1A -Q 1F  Q uality  G uidelines of The International C ouncil for H arm onization of Technical 
Requirem ents for Pharm aceuticals for Hum an Use (ICH). The guideline concerning the Photostability 
Testing of N ew  Drug Substances and Products— Q1B was im plemented in Europe on 1 Decem ber 1996 
and in the USA on 1 M ay 1997 [20]. The photoinstability of a drug could im pact its effectiveness and 
lead to the formation of products w ith unknown activity [21]. The lack of detailed inform ation about the 
photostability of tazarotene prompted us to perform  in-depth research on this third-generation retinoid.
Tazarotene is considered to be photostable; however, it is specifically used by young people who 
spend a lot of tim e outside and are exposed to U V  irradiation, w hich  increases the frequency of the 
sim ultaneous use of U V  filters. H ence, there is an urgent need to study the interactions betw een 
tazarotene and U V  absorbers under U V  irradiation. The present study aim ed to assess the im pact of 
selected UV absorbers extensively used in sunscreens and cosmetics on the photostability of tazarotene 
in ethanol solutions under U V  irradiation. Benzophenone com pounds w ere chosen due to their 
w idespread em ploym ent in cosm etics, photostability, and w ide-ranging spectrum  protection against 
not only  U V B (290 -320  nm ) in particular bu t also UVA (32 0 -4 0 0  nm ) [22,23]. O ut o f the tw elve 
benzophenone-type U V  absorbers, the follow ing four w ere selected for this study: benzophenone-1, 
benzophenone-2, benzophenone-3 (oxybenzone), and benzophenone-4 (sulisobenzone). Additionally, 
avobenzone, w hich is one of the m ost com m on UVA filters, w as investigated. D ue to its rapid 
photodegradation, avobenzone should be included w ith a stabilization agent— such as octocrylene [24]. 
Furtherm ore, an assessm ent of the effect of TiO 2 and ZnO  nanoparticles, w hich  could be used as 
physical U V filters in sunscreens, on the stability of tazarotene under U V irradiation w as perform ed. 
According to the regulations of the US Food and Drug Adm inistration (FDA), ZnO and TiO2 are used in 
sun protection products in maximum concentration up to 25% [25]. It is universally accepted that ZnO 
and TiO2 as sem iconductors could be used in heterogeneous photocatalysis [26,27]. Both the oxides 
d isplay high photocatalytic activity  and are chem ically  and photochem ically  stable. N evertheless, 
there is very little inform ation in the research literature about the potential photocatalytic degradation 
products of tazarotene. The overarching goal of the conducted in vitro tests w as to determ ine the
plausible structures of the photoproducts form ed u nder experim ental conditions and to evaluate 
their cytotoxicity.
2. M aterials and M ethods
2.1. Reagents
Tazarotene (ethyl 6-[2-(4,4-dim ethyl-2,3-dihydrothiochrom en-6-yl)ethynyl]pyridine-3-carboxylate) 
w as purchased from Sigm a-Aldrich (St. Louis, M O, USA). H igh-perform ance liquid chrom atography 
(H PLC )-grade m ethanol, acetonitrile, and form ic acid (98% ) w ere purchased from  J.T. Baker 
(Phillipsburg, NJ, USA). Ethanol absolute for HPLC >99.8%  w as obtained from POCH (Gliwice, Poland). 
Water (quadruple-distilled) with a conductivity of less than 1 gS cm -1 was prepared using the S2-97A2 
distillation apparatus (C hem Land, Stargard Szczecin , Poland). Zinc oxide (nanopow der < 1 0 0  nm  
particle size) and titanium  (IV) oxide (anatase, nanopow der <  25 nm  particle size, 99.7%  trace m etals 
basis) were purchased from Sigm a-Aldrich (St. Louis, M O, USA). The UV absorbers— benzophenone-1, 
benzophenone-2, benzophenone-3, benzophenone-4, avobenzone, and octocrylene— w ere obtained 
from Sigm a-A ldrich (St. Louis, M O, USA).
2.2. Reagent Solutions Preparation
The stock solution of tazarotene w as prepared a t a concentration of 0.2 m g m L -1 in a 50-m L 
volumetric flask by dissolving the weighted portion of the standard substance in ethanol and was then 
stored at 2 -8  °C for no longer than three days. For the method validation, six solutions w ith tazarotene 
concentrations of 0.01, 0.025, 0.05, 0.1, 0.15, and 0.2 m g m L -1 w ere prepared. For the assessm ent of 
photocatalytic degradation, suspensions of TiO2, ZnO, or TiO2/ZnO (1:1, w/w) in ethanol were prepared 
before each experim ent by  adding 100 m g of oxide to 5 m L of ethanol and w ere then sonicated in an 
u ltrasonic bath  for 3 m in. The solutions of organic U V  absorbers w ere m ade a t a concentration of 
1 m g m L-1 .
2.3. Photostability Assessm ents
The investigated solutions were placed in quartz Petri dishes w ith 0  50 X 12 mm (Hornik, Poznan, 
Poland), w hich w ere protected against evaporation w ith parafilm . The irradiation experim ents w ere 
carried out in a solar light sim ulator (Suntest C P S+ , Atlas, Germ any) w hich included an optical filter 
cutting off w avelengths shorter than 290 nm  and an infrared-block filter to m inim ize the therm al 
effects. The samples w ere irradiated for 1 h at 500 W  m -2 (cumulative dose of UV radiation 218 kJ m -2 ). 
For photostability  analyses of tazarotene in ethanol, 2 m L of the investigated solution at a final 
concentration of 0.1 m g m L-1 w as irradiated.
Photocatalytic degradation tests w ere perform ed by adding 1 m L of tazarotene solution, 0 .5  m L 
of one of the prepared suspensions of TiO2, ZnO , or TiO2/Z nO  along w ith  the right am ount of 
ethanol to achieve the final concentration of tazarotene. A fter the stipulated tim e of irradiation, 
the quartz dishes were w ithdrawn, and the samples were filtered through 0.45 gm syringe filters before 
the u ltra-perform ance liquid chrom atography-tandem  m ass spectrom etry (U PLC -M S/M S) analysis. 
A nalogously prepared sam ples, w hich  w ere protected w ith  alum inum  foil before irradiation, w ere 
used as the dark control. For UV absorbers, analogously prepared solutions containing 1 mL of 0.2 mg 
m L-1 tazarotene solution, 0.8 m L of ethanol, and 0.2 m L of benzophenone-type U V absorber solution 
in ethanol or 0.1 mL of avobenzone +0.1 mL of octocrylene w ere exposed to UV irradiation in a solar 
light simulator.
2.4. In Vitro Cytotoxicity Assays
2.4.1. Investigated Solutions
The stock solution of tazarotene in ethanol w as prepared in  a 10-m L flask at a concentration of 
10 m M . The prepared sam ples containing 2 m L of the above solution w ith  the additional 10 m g of 
TiO2/Z nO  (1:1, w/w) w ere placed into quartz dishes. The sam ples w ere irradiated for 0 .5 ,1 , and 2 h 
in a solar light sim ulator. Later, the sam ples w ere filtered through a 0.45 gm  filter and subjected to 
cytotoxicity testing.
2.4.2. Cell Lines and Cell Growth Inhibitory A ssay
H um an cancer cell lines isolated from  breast (M D A -M B-231), cervix (H eLa), and ovary (A2780) 
cancers w ere purchased from  European C ollection of Cell Cultures (EC C A C, Salisbury, UK). 
C ells w ere cultivated in m inim al essential m edium  supplem ented w ith  10% fetal bovine serum , 
1% antibiotic-antim ycotic m ixture, and nonessential am ino acids. A ll m edia and supplem ents w ere 
obtained from  Lonza G roup Ltd. (Basel, Sw itzerland). N ear-confluent cells w ere seeded onto 
a 96-w ell m icroplate at a density  of 5000 cells/w ell, and after overnight standing, new  m edium  
containing the tested substance w as added. A fter incubation for 72 h at 37  °C in  hum idified air 
containing 5%  C O 2, the v iability  of the cells w as determ ined by the addition of 20 gL of M TT 
(3-(4,5-dim ethylthiazol-2-yl)-2,5-diphenyltetrazolium  bromide, 5 mg m L-1 ) solution. After a 4h contact 
period, the m edium  w as rem oved, and the precipitated form azan crystals w ere dissolved in  100 gL 
of d im ethyl sulfoxide (D M SO ) during a 60 m in period of shaking. Finally, the produced form azan 
w as assayed at 545 nm , using a m icroplate reader utilizing w ells w ith  untreated cells as control [28] . 
A ll in vitro experim ents w ere carried out on two m icroplates w ith at least five parallel wells.
2.5. In Silico Toxicity Prediction
O SIR IS Property  Explorer w as used to predict m utagenicity, tum origenicity, irritation, 
and reproductive effects of tazarotene and its eleven photocatalytic degradation products [29]. 
The investigated structures w ere used to predict the toxicity risks related to the specific risk category.
2.6. Ultra-Perform ance Liquid Chrom atography-Tandem  M ass Spectrom etry Analysis
The U P L C -M S/M S system  equipped w ith  a W aters A C Q U ITY®  U PLC®  (W aters C orporation, 
M ilford, M A, USA) and a Waters TQD mass spectrom eter (electrospray ionization (ESI) m ode tandem 
quadrupole) w as used for the analysis. The investigated compound w as analyzed on a Acquity UPLC 
BEH  (bridged ethyl hybrid) C18 colum n (2.1 X 100 m m , 1.7 gm ), com prising an A cquity U PLC  BEH  
C18 VanGuard precolum n (2.1 X 5 m m , 1.7 gm ) eluted under gradient conditions using 95%  to 0% 
of eluent A  over 10 m in, a t a flow  rate of 0.3 m L m in-1 . The colum n tem perature w as m aintained 
at 40 °C. Eluent A  w as w ater/form ic acid (0.1% , v/v), w hile eluent B w as acetonitrile/form ic acid 
(0.1%, v/v). Chrom atogram s w ere acquired using a W aters eA PDA detector. The concentration (%i) of 
tazarotene after its degradation w as calculated as the quotient of the peak area (Ai) to the sum  of all 
peak areas (£ A )  on chrom atogram s according to the form ula, % i =  (A i/(£ A ) X 100). In the case of 
organic U V  absorbers, the individual peak areas of the analyzed U V  filters w ere not included in the 
total peak area. Chrom atogram s w ere recorded using the W aters eA PD A  detector. The spectra w ere 
analyzed a t 2 0 0 -700  nm  w ith  1.2 nm  resolution and a sam pling rate o f 20 points s-1 . M S detection 
settings of W aters TQ D  mass spectrom eter w ere as follows: source tem perature— 150 °C, desolvation 
tem perature— 350 °C, desolvation gas flow  rate— 600 L h -1 , cone gas flow — 100 L h -1 , capillary 
potential— 3.00 kV, and cone potential— 30 V. Nitrogen was used for both nebulizing and drying gases. 
The optimum collision energy was determined to be 50 eV. The ion spectra w ere obtained by scanning 
from 50 to 350 m/z. M assLynx V  4.1 (Waters) softw are w as used for data acquisition.
2.7. Statistical Analysis
Statisti cal onalyses were performed using Statistics v. 12 (StatSoft) an d GraphP ad Prism (CGraphPad 
6 Software, S in  Diego, CA, USA). For analysis of cell deoth, two-way analysis of variance w ith Tukey's 
m ultiple com parisons test w as carried out. D ifferences w ere considered statistically significant in 
com parison w ith untreated controls at p <  0.05.
3. Results and D iscussion
3.1. M ethod Validation
The main objective of applying the UPLC method was to confirm its applicabilify for the assessm eni 
of tazarotene in the presence of fts degradation products. The developed meShod w as suftable for 
determining tazarotene and fts degradation products in the tested efhanolic solutions. The specificity of 
the method was evaluated through the assessment of blank chromatogr oms, chromat ograms of the pure 
standard substance, and chrom atograms of tazarotene after degradation. Fu rthermore, tire resolution of 
the investiga ted benzophenone-iype UV fi lters, avobenzone, octocrylene, and -azarotene w as verified. 
The chrom atographic sepatation of the other selected UV filters and tazasotene wab satisfactory, both 
before and affer U V  irradiation (Figure t ) . The results w ere validated  for linearity, precision, and 
accuracy [S5]. Lrast squares linear regreesion was; perform ed to statistically evaluafe the relationship 
betw een the pea k areas and the concentration of bexarotene. "The iinearity  w as d eterm ined for the 
concentration oange from  0.01 So 0.2 m g m L -1 , w ith  a correlation coefiesient and a  determ ination 
coefficient (R2 l of n.9991 and 0.9982, respectively. Tire Shapiro-W ilk  trs t w as used to validate the; 
norm ality assumption; the significance value (p =  0. 1715f) w as greater than 0.05, and hencet the residualf 
w ere considered to be norm ally  distributed. The precision determ ined from  the analysis o l the rix 
replicates of tazarotene sotutions a l a single concentration of 0.1 m g m L“1 w as low  er than 1.29% 
(%RSD), otid the recovery rate at three concenlration levels (80%, !00% , and 120%) ranged from 97.5% 
to 101.90%.
Figure 1. High-performance liquid chromatography chromatograms of tazarotene (TAZ) following 
UV irradiation in the presence of selected UV absorbers: (A) tazarotene standard, (B) tazarotene with 
sulisobenzone (BP-4), (C) tazarotene with TiO2 and ZnO (TP- degradation products of tazarotene),
(D) tazarotene with benzophenone-2 (BP-2).
3.2. Identification o f  Photocatalytic Degradation Products o f  Tazarotene
The im pact of U V  irradiation on tazarotene photostability  in the presence of TiO2 and/or ZnO  
nanoparticles w as asses sed. The photocatalytic degradotion products of tazarotene w ere identified 
w ith  the help of the U P L C -M S/M S analysis and supported w ith  fragm entation patterns obtained 
from  M S/M S experim ents. Table 1 presents the proposed structures of the degradation products, 
and Table 2 depicts the proposed fragm entation patterns of tazarotene and its degradation products. 
It w as found that the degrada tion process ma inly affec ted the 4,4-tlim ethyls3,4-dihydro-2 H -thiopyran 
moiety. The fragm ents m ost susceptible to oxidation w ere the m ethyl groups and the sulfur atom . 
The; oxidation of m ethyl groups led to the d egradatinn products— TP-1 -T P -5 , TP-7, TP-9, and TP-10. 
The oxidation of the sulfur atom  td su lfoxide and sulfone m oiety  w as observed for the degra dation 
products T P H -T P ^  ultimately resul ting; in the alimination oT the sulfur-containing moisty, as observetl 
for products TP-9 find TP-10. The elim ination erf the ester m oiety w as observed only for the m inar 
product— TP-11. TP -6 and TP-8 w ere the earliest appearing produces and dom inant in term s of 
ejfuantity. TP-6 has also been  regarded as a hypothetica1 product of p ersxid e oxid atien  or photolytis 
expusure of tazarotene [30]. In 2020, a publication about the degradation chem istry of tazarotene was 
published, in  w hich eleven degradation products of the investigated drug w ere characterized [31]. 
Furced degradation studies included the photolytic degradation of tazarotene in the following solutions: 
0.1 M  H Cl, 0.1 la1 N aO H , or C H 3C N U 2O (8°:20, v/vl, and tazarotene in the solid state. TP-6 w at one 
of the presum ed products o f photolysis in acid and neutral conthtions. The oxidative degradation 
of tazaootene perform ed in  3%  H 2O 2 at room  tem perature gave rise to tw o jnsodurfs w ith  the m ass 
of protona ted form s— m/z 368.1308 and 384.1258., corresponding to TP -6 and TP-8, respectively  [31]. 
A nalysis of the synthesis and degradation process of tazarotene revealed four i m purities, including 
transform ation to TP-6 and TP-81 through exidation [4]. Exposure of tazarotene to 1.2 milfion lux hourr 
resulted in the degradation of 8.85% of the initial quantity w ith the form ation— m ainly Im p-B, that is 
TP-6 [32]. We did not identify tazarotenir acid, the active m etabolite of taearotene, w hich is the m ajor 
degradation product formed during hydrolysis [4,26,33]. Tazarotenic acid does not accum ulate in the
body over tim e. The concentrations of tazarotenic acid in  the plasm a of patients w ith psoriasis w ere 
found to be 0.45 ±  0.78 pg L-1 (after 0.05% tazarotene gel) and 0.83 ±  1.22 pg L-1 (after 0.1% tazarotene 
gel) [8 ]. The m axim um  average plasm a concentrations of tazarotenic acid after topical applic ation of 
0.1% of tazarotene cream on the face were less than 0.25 pg L-1 [34]. It is metabolized to sulfoxide and 
more polar compounds and eliminated from the body via urine and feces [3,8]. The binding to plasma 
proteins, w hich plays a key role in the distributi on, elimina tion, and therapeutic effectiveness of drugs, 
w as greater than 99% [8 ]. After topical adm inistration, iazarotrne and tazarotenic acid m etabolize via 
oxidation to sulfoxides, sulfonee, and other polar m etebolites [8,35]. lit appears that there are som e 
sim ilarities betw oen tiret know n in vivo m etabol ic pathw ays of tnzaaotene and those pontulatad for 
its in vitro photocaialytic degradation. In both the caaes, the sulfoxide (TP-6 i and sulfone (TP-8 ) of 
tazarotene w ere identified.
Table 1. Proposed structures of the degradation products of tazarotent.
Compound RT (min) [M+H+] Fragmentation Ions Structure
TP-6 6.30 368.1 280.1,296.1, 308.2, 340.1
TP-7 6.62 430.1 294.1,338.0, 366.1, 384.1,412.1
TP-8 6.97 384.1 356.1
TP-9 7.47 36(5.1 262.1,280.1, 269.1, 340.1
TP-10 8.49 366.1 252.1,280.1, 294.1,338.1
Tazarotene 9.28 352.1 222. 1,266.1, 294.1, 308.2, 324.1
TP-11 9.60 280.1 136.2, 156.1,236.1
Tazarotene
TP-1





3.3. U V Irradiation o f  Tazarotene in the Presence o f  Organic U V  Absorbers
The im pact of U V  irradiation on tazarotene stability in  the presence of benzophenone-type UV 
filters w as assessed. Benzophenone-1, benzophenone-2, benzophenone-3, and benzophenone-4 were 
selected for the study. Besides, the com bination of avobenzone and octocrylene was also tested in this 
experim ent. This is a popular com bination of U V  filters w idely  used in  sunscreens. To balance the 
instabitity of avobenzone, octocrylene acts as a photostabilizar and UV absorber. Two ef the investigated 
benzophenones— oxybenzono and sufisobenzone— w ith peak absorption Amsx equal to 286 and 324 nm 
have been  approved by  the FDA. A ccording So She FD A  regulations, the m axim um  recom m ended 
concentrations of benzophenone-3, benzophenone-4, avobenzone, and octocrylene are 6%, 10%, 3%, 
and 10%, respectively  t25]. Figuro 2 displays the relative peak areae of tazarotene to ifiustrate the 
im pact of U V  absorbers on its y hotostability under experim enial conditions . Tazarotene was stable in 
all cases, excluding tu lisobenzone, w here a slight degradation w as observsd. Two additional peaks 
w ere identified on the chrom atogram s (Figure IB ), and two peaks in the spettcum  w ere at m/z 412.18 
(TP-1) and 368.18 (TP-6). 'Tire degradation procets occursed throughthe oxidation of ihe sulfur atom  to 
sulfoxide and fire subsequenS oxidation of tho m ethyl groups. N o p h otod eg rtd ation  products w ere 
observed in all the dark centrol samples, w hich indicote the stability ot tazerotene in the absence of UV 
irradiation under the applied c onditions.
Figure 2. The relative peak area of tazarotene following UV firsdiation in the presence of UV absorbers: 
BP-1 (benzophenone-1), BP-2 (btnzophenone-2), BP-3 (benzsphenone-3), BP-4 (benzophenone-4), and 
AVO + OCT (avobenzone + octocrylene).
3.4. Cytotoxic R isk A ssay
Figure 3 depicts the relative peak area of tazarotene and its photocatalytic degradation products 
presented in chrom atogram s follow ing 0.5, 1, and 2 h of U V  irradiation of the exam ined solutions. 
The leading products present in all chrom atogram s w ere TIP-6, TP -8, and TIP-10. A fter 2 h of U V 
irradiation of the investigated solutions, all the identified phototransform ation products of tazarotene 
w zre noted on chrom atogram s.
Figure 3. Average relative peak areas of tazarotene and its main photocatalytic degradation products 
identified in the tested solutions after 0.5, 1, or 2 h of UV irradiation in the presence of TiO2/ZnO.
TAZ—tazarotene; TP-3, TP-5, TP-6, TP-8, and TP-10—photocatalytic degradation products of tazarotene.
The cell grow th-inhibitory  activities of tazarotene follow ing its photocatalytic degradation in 
experim ental conditions w ere determ ined in vitro against cervical (HeLa), boeast (M DA-M B-231), and 
ovary (A 2780) cancer cell lines by  m eans of M TT assays. Cella w ere treated w ith  3, 10, and 30 pM 
solution ćifter UV/- ireadiation (T0— w ithout irradiation, T1— e.5 h, T2— 1 h, and T3— 2 h). The 3esults 
are shown in Figure 4 . The in -vitro cytotoxic ity risk: evaluation bahed on the photocatalytic degradation 
of tazarotene indicated the anti proliferative action at the concentration of 30 dM. A2780 cells exhibited 
substantial g rowth inhibiti on by 30 pM tazarotene withoua irradiation followed by a biphasic action in 
term s of the irradiation tim e. Sam ples of lnw er concentrations (3 and 10 pM) resuhed ln d m ode st 
increase of proli fer ation. T3 solu tions genera lly more effectively inhib i ted cell prolifer ati on th an other 
sam ples, w hich indicated that antiproliferative m etabolites could be generated, duriny irradiation in 
a tim e-depe n d e n  m anner. The behavior of H eLa cells w as untque w ith  a concenarationsdependent 
actien of tazarotene w ith no irradiation w hich wns substantially lesh after 0 .5 -2  h of irrad iation
Figure 4. Changes in the cell viability of HeLa, A2780, and MDA-MB-231 cancer cells caused by the 
solutions of tazarotene following photocatalytic d egradation. Cells ‘were treated with 3,10, anti 30 <iM 
solutions of ta zarotene after UV irradiation (TO—without irradiation, T1—0.5 h of irrad iation, T2—l h 
of irradiation, and T3—2 h of irradiation): * p <  0.05, ** p <  0.01, and *** p <  0.00 1.
3.5. In Silico Toxicity Predictions
In the next step of the; study, the O SIRIS Iro p erty  Explorer server w as daployed to calculate 
the toxicities of taaarotene and all its identified photodecom position products generated under 
experimental conditions. Table 3 presents the outcomes of the toxicity risk assessmsnt. Five degrad ation 
products— TP-2k TP-3, TP-4, TP-7, and TP-8— could be harm ful in termo of the reproductive 
effects, w hich it atsociated w ith 3,4-dihydro-6-methyl-2Hl-1-benzothiopyran lf -d to x id e , w hile gne of 
them — TP-10— dem onstrated potential irritant activity.
Table 3. Toxicity risk assessment of the photocatalytic degradation products of tazarotene (TP-1-TP-11) 
performed using OSIRIS Property Explorer.
Compound Mutagenic Tumorigenic Irritant Reproductive Effective
Tazarotene - - - -
TP-1 - - - -
TP-2 - - - + / -
TP-3 - - - + / -
TP-4 - - - + / -
TP-5 - - - -
Compound Mutagenic Tumorigenic Irritant Reproductive Effective
TP-6 - - - -
TP-7 - - - + / -
TP-8 - - - + / -
TP-9 - - - -
TP-10 - - + / - -
TP-11 - - - -
(-) None, (+/-) Medium.
4. Conclusions
The presented results show  the significance of the photostability  studies for topical agents 
applied to the skin. Tazarotene, a receptor-selective, th ird-generation retinoid, is com m only used as 
m onotherapy and included in com bination therapy for acne vulgaris and psoriasis. This study revealed 
the im pact of the presence of U V  absorbers on the photostability  of tazarotene in ethanol solution 
under U V  irradiation. The photodecom position of tazarotene in the presence of TiO2, ZnO , and 
sulisobenzone w as observed under the applied experimental conditions. Furtherm ore, the presumable 
structures of photocatalytic degradation and photodegradation products of tazarotene w ere identified 
for the first time. The in silico toxicity testing of degradation products indicated their theoretical toxic 
reproductive effects and irritant activity. The photostability studies provided valuable inform ation to 
optim ize the m anufacturing process as w ell as to ensure the safe use of m edications by  patients. It is 
worth mentioning that UV filters act as photostabilizers but could also contribute to the degradation of 
active pharm aceutical ingredients u nder U V  irradiation. Therefore, further efforts should be taken 
to verify  the potential im pact of U V  irradiation on different com positions of substances used in 
topical preparations.
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